ArticlePloS one2015
Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 55 citations in OpenAlex.
- Trial
- Tracking the soluble biomarkers of MIS-C and their association with clinical parameters and severity.Pediatric research · 2026Article
- Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis.Circulation research · 2025Article
- Changes in the Release of Endothelial Extracellular Vesicles CD144+, CCR6+, and CXCR3+ in Individuals with Acute Myocardial Infarction.Biomedicines · 2024Article
- miR-6089 may prevent the inflammatory events leading to cardiovascular disorders in RA patients.Heliyon · 2024Article
- NRASPediatric blood & cancer · 2024Article
- The relationship between inflammatory factors and heart failure: evidence based on bidirectional Mendelian randomization analysis.Frontiers in cardiovascular medicine · 2024Article
- The role of circulating cytokines in heart failure: a bidirectional, two-sample Mendelian randomization study.Frontiers in cardiovascular medicine · 2024Article
- A Mendelian randomization study on the association between systemic inflammatory regulators and essential and secondary hypertension.Frontiers in cardiovascular medicine · 2024Article
- CXCL9 and its Receptor CXCR3, an Important Link Between Inflammation and Cardiovascular Risks in RA Patients.Inflammation · 2023Article
- Reprograming of transcriptional profile of colonic organoids from patients with high blood pressure by minocycline.American heart journal plus : cardiology research and practice · 2023Article
- Predictors of chronic thromboembolic pulmonary hypertension in patients with submassive pulmonary embolism treated with catheter-directed thrombolysis versus anticoagulation alone: A secondary analysis of the SUNSET sPE trial.Journal of vascular surgery. Venous and lymphatic disorders · 2023Article
- Inflammatory cytokines and chemokines in obese adolescents with antibody against to adenovirus 36.Scientific reports · 2023Article
- Pilot Biomarker Analysis and Decision Tree Algorithm Modeling of Patients with Chronic Subdural Hematomas.Neurotrauma reports · 2023Article
- Article
- Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris.Experimental dermatology · 2022Article
- Accelerated epigenetic aging and inflammatory/immunological profile (ipAGE) in patients with chronic kidney disease.GeroScience · 2022Article
- Inflammatory marker trajectories associated with frailty and ageing in a 20-year longitudinal study.Clinical & translational immunology · 2022Article
- Evolution, Expression and Functional Analysis of CXCR3 in Neuronal and Cardiovascular Diseases: A Narrative Review.Frontiers in cell and developmental biology · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detecting left ventricular (LV) dysfunction at an early stage is key in addressing the heart failure epidemic. In proteome profiling experiments in mice subjected either to aortic banding or sham, the circulating CXCR3 ligands monokine induced by interferon-γ (MIG) and interferon-γ inducible protein 10 (IP10) were 5 to 40 fold up-regulated at eight weeks. We assessed the diagnostic value of circulating NT-pro BNP and CXCR3 ligands (MIG, IP10, Interferon-inducible T-cell alpha chemo-attractant [I-TAC]) in patients with hypertension (≥140/90 mm Hg) associated with subclinical (n = 19) or symptomatic (n = 16) diastolic LV dysfunction on echocardiography and healthy controls. NT-pro BNP, MIG, IP10, I-TAC all increased (p ≤ 0.014) across the categories of worsening left ventricular dysfunction. In patients with symptomatic disease, MIG, IP10, and I-TAC increased 210% (p = 0.015), 140% (p = 0.007) and 120% (p = 0.035) more than NT-pro BNP. The optimal discrimination limits, obtained by maximizing Youden's index were 246 pmol/L, 65 pg/mL, 93 pg/mL, and 24 pg/mL, respectively. The odds ratios associated with the four biomarkers were significant (p ≤ 0.010), ranging from 4.00 for IP10 to 9.69 for MIG. With adjustment for NT-pro BNP, the CXCR3 ligands retained significance (p ≤ 0.028). Adding optimized thresholds for the CXCR3 ligands to NT-pro BNP enhanced (p ≤ 0.014) the integrated discrimination improvement and the net reclassification improvement. In conclusion, congruent with the concept that inflammation plays a key role in the pathogenesis of LV dysfunction, MIG, IP10 and I-TAC add diagnostic accuracy over and beyond NT-pro BNP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.